Day: November 14, 2019

HOUSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) — TC PipeLines, LP (NYSE: TCP) (the Partnership) will participate at the RBC Capital Markets 2019 Midstream Conference on Wednesday and Thursday, November 20 and 21, 2019 in Dallas, Texas. Nathan Brown, President of TC PipeLines GP, Inc., the Partnership’s general partner, will attend and meet with investors during the conference.A copy of the meeting materials will be available on the morning of November 20, 2019 in the Investor Center section of the Partnership’s website at http://www.tcpipelineslp.com/events-and-presentations.html.About TC PipeLines, LPTC PipeLines, LP is a Delaware master limited partnership with interests in eight federally regulated U.S. interstate natural gas pipelines which serve markets in the Western, Midwestern and Northeastern United States. The Partnership is...

CAMPBELL, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (OTCQB: KULR) (the “Company” or “KULR”), a leading developer of battery safety and thermal management technologies, announced it will collaborate with a global Tier-1 power tool manufacturer on innovations that will improve motor speed while extending longevity in a new line of brushless DC motor (BLDC) products.  When motors run they produce heat which can slow or drain the power transfer from the battery and wear down essential components. Reducing heat, by drawing it away from a source, can increase power transfer and help motors run faster and more efficiently for longer. To reduce the impact of heat and increase performance of their upcoming suite of high-performance BLDC power tools, this Tier-1 manufacturer plans to apply KULR’s proprietary Fiber...

Topline results expected before the end of Q1/2020REHOVOT, Israel and NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) — Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, and Amarantus Bioscience Holdings, Inc. a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that their joint venture company, Breakthrough Diagnostics, Inc. has completed enrollment of its ongoing clinical trial evaluating the relationship of Alzheimer’s blood diagnostic Lymphocyte Proliferation Test (LymPro Test™) with amyloid PET neuroimaging at Leipzig University in Germany (the ‘LymPro...

At a meeting of the Board of Directors on 14 November 2019, the Board and CEO approved the interim financial statements of the Kvika banki hf. group for the period from 1 January to 30 September 2019.Good results for first nine months of the yearProfit before taxes amounted to ISK 1,996 millionProfit after taxes amounted to ISK 1,913 millionReturn on equity was 20.3%Net operating income amounted to ISK 5,615 millionOperating expenses amounted to ISK 3,899 millionTotal assets amounted to ISK 112.6 billionThe group’s equity amounted to ISK 14.8 billionThe equity ratio at the end of September was 22.9%, but 23.6% when profit for the quarter is taken into accountThe Liquidity Coverage Ratio (LCR) was 260%Total assets under management amounted to ISK 417 billionThe number of full-time employees at the end of September was 122A presentation for...

Á stjórnarfundi þann 14. nóvember 2019 samþykktu stjórn og forstjóri árshlutareikning samstæðu Kviku banka hf. fyrir tímabilið 1. janúar 2019 til 30. september 2019.Góð afkoma á fyrstu níu mánuðum ársinsHagnaður fyrir skatta nam 1.996 milljónum krónaHagnaður eftir skatta nam 1.913 milljónum krónaArðsemi eiginfjár var 20,3%Hreinar rekstrartekjur námu 5.615 milljónum krónaRekstrarkostnaður nam 3.899 milljónum krónaHeildareignir námu 112,6 milljörðum krónaEigið fé samstæðunnar nam 14,8 milljörðum krónaEiginfjárhlutfall í lok september var 22,9% en 23,6% að teknu tilliti til hagnaðar á fjórðungnumLausafjárþekja (LCR) var 260%Heildareignir í stýringu námu 417 milljörðum krónaStarfsmenn í fullu starfi voru 122 í lok septemberKynningarfundur fyrir markaðsaðila og hluthafa verður haldinn í höfuðstöðvum Kviku, Borgartúni 25, föstudaginn 15. nóvember...

DALLAS, Nov. 14, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today highlighted GW Pharmaceuticals $3.5 Billion market capitalization.  GW Pharma’s cannabis biopharmaceutical technology is featured today in a ZACHS Investment Research article. KALY has a U.S. Patented Cannabis Extraction Process and is developing treatments for various medical conditions (see below).  Doctors working with KALY on the treatment developments have compared KALY’s technology to GW Pharma’s and indicated the KALY solutions could be superior to GW Pharma’s.  KALY has recently announced receiving inquiries into the acquisition of the company’s cannabis biopharmaceutical technology valuing the technology at $50 million.  KALY management is entertaining the inquiries but indicates...

SASKATOON, Saskatchewan, Nov. 14, 2019 (GLOBE NEWSWIRE) — Royal Helium Ltd. (“Royal” or the “Company”) (TSXV: RHC) announces that it has been granted by the Government of Saskatchewan, an undivided, 100% crown interest in a new helium permit covering 17,676 hectares adjacent to and immediately west of the Company’s Climax property. The Company plans to proceed with a geotechnical and seismic program over “Climax West”, land extended with the newly acquired helium permit. The program will be conducted in the same manner as Climax East with the goal of identifying other structural traps within the same known zone and to increase Royal’s drill target inventory. Program details will be announced once finalized.Royal recently completed its first phase of exploration on the Climax East property isolating an approximate 3,094-hectare basement...